CSI Market
Sign In | Register

Phoenix Biotech Acquisition (PBAXU) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PBAXU Annual Cash Flow →
This cash flow overview for Phoenix Biotech Acquisition spans from Mar 31 2025 to Jun 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-28.44
Depreciation & amortization0.12
Amortization of Other Assets0.75
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation2.74
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.00
Unrealized Gain On Marketable Securities Held In Trust Account-
Gain From Settlement Of Liabilities With Vendors-
Operating Lease Right Of Use Asset Amortization Expense0.21
Gainloss On Revaluation Of Warrant Liability-
Increase Decrease In Operating Lease Liability-0.24
Inducement Expense-
Gain On Revaluation Of Earnout Liability-0.02
Inducement Expense-
Derivative Gain Loss On Derivative Net0.90
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Income Taxes0.00
Increase (Decrease) in Accounts Payable0.64
Increase (Decrease) in Accrued Liabilities0.12
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.46
Other Working Capital-0.32
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities19.77
Discontinued operations0.00
Net Cash flow from Operating Activities-5.09
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Trust Preferred Investments0.00
Real Estate Investments0.00
Proceeds from Sale of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale and Maturity of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net3.66
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.70
Common Stock Subscriptions Deposit-
Advances From Shareholder-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents1.66
Proceeds From Exercise Of Series A Preferred Warrants-
Proceeds From Collection Of Stock Subscriptions Receivable-
Proceeds Received From Sale Of Series B Preferred Stock-
Proceeds Received From Sale Of Series D Preferred Stock Net Of Issuance Costs-
Payment Of Deferred Offering Costs-
Proceeds Received From Sale Of Series B Shares Net Of Issuance Costs-
Proceeds Received From Sale Of Series C Preferred Shares Net Of Issuance Costs-
Proceeds Received From Sale Of Series D Preferred Shares Net Of Issuance Costs-
Proceeds Received From Sale Of Series E Preferred Shares Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.36
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.09
Total Cash Flow-0.72
4 historic quarters locked

Sign in to unlock the full Phoenix Biotech Acquisition cash flow history.

Sign In Create Free Account

About Cero Therapeutics Holdings Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-090030

Figures are derived from filed reports and may be restated. Historical data is subject to revision.